Juncture Wealth Strategies LLC Buys Shares of 8,082 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Juncture Wealth Strategies LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,082 shares of the company's stock, valued at approximately $1,065,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Diversified Trust Co boosted its position in shares of Neurocrine Biosciences by 12.6% during the fourth quarter. Diversified Trust Co now owns 2,381 shares of the company's stock worth $314,000 after buying an additional 267 shares during the period. Red Spruce Capital LLC boosted its position in shares of Neurocrine Biosciences by 0.6% during the fourth quarter. Red Spruce Capital LLC now owns 16,026 shares of the company's stock worth $2,112,000 after buying an additional 101 shares during the period. FCF Advisors LLC acquired a new position in shares of Neurocrine Biosciences during the fourth quarter worth about $1,157,000. Symmetry Partners LLC acquired a new position in shares of Neurocrine Biosciences during the fourth quarter worth about $246,000. Finally, Sunbelt Securities Inc. boosted its position in shares of Neurocrine Biosciences by 34.3% during the third quarter. Sunbelt Securities Inc. now owns 325 shares of the company's stock worth $37,000 after buying an additional 83 shares during the period. 93.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. The Goldman Sachs Group upped their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a "buy" rating in a research report on Thursday, January 25th. Citigroup reduced their price target on Neurocrine Biosciences from $141.00 to $140.00 and set a "neutral" rating for the company in a research report on Thursday, February 8th. StockNews.com raised Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 8th. Mizuho increased their target price on Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, February 8th. Finally, Stifel Nicolaus increased their target price on Neurocrine Biosciences from $141.00 to $144.00 and gave the stock a "buy" rating in a research note on Monday, December 18th. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $137.52.

Insider Activity at Neurocrine Biosciences

In related news, CEO Kevin Charles Gorman sold 105,835 shares of the firm's stock in a transaction on Monday, January 8th. The stock was sold at an average price of $132.44, for a total transaction of $14,016,787.40. Following the sale, the chief executive officer now owns 499,754 shares of the company's stock, valued at approximately $66,187,419.76. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 200 shares of Neurocrine Biosciences stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $140.00, for a total transaction of $28,000.00. Following the transaction, the insider now directly owns 7,507 shares of the company's stock, valued at approximately $1,050,980. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin Charles Gorman sold 105,835 shares of Neurocrine Biosciences stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $132.44, for a total value of $14,016,787.40. Following the transaction, the chief executive officer now directly owns 499,754 shares in the company, valued at $66,187,419.76. The disclosure for this sale can be found here. Insiders have sold a total of 334,055 shares of company stock valued at $44,856,373 in the last 90 days. 4.40% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Down 0.0 %

Shares of NBIX stock traded down $0.06 during trading hours on Friday, reaching $139.10. The company's stock had a trading volume of 1,733,666 shares, compared to its average volume of 851,790. The firm's 50 day simple moving average is $135.89 and its 200-day simple moving average is $122.31. The company has a market capitalization of $13.84 billion, a price-to-earnings ratio of 58.42, a PEG ratio of 0.91 and a beta of 0.25. Neurocrine Biosciences, Inc. has a fifty-two week low of $89.04 and a fifty-two week high of $143.35.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating analysts' consensus estimates of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The company's revenue was up 25.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.88 EPS. Sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.86 earnings per share for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.